Press release
Crohn's Disease Market Across the 7MM to Witness Upsurge in Growth from USD 9 Billion in 2023 | DelveInsight
The Crohn's disease market is predicted to grow substantially in the 7MM, which includes the United States, EU4-Germany, France, Italy, and Spain-the United Kingdom, and Japan. This growth is attributed to several factors, including the increasing prevalence of Crohn's disease, advances in research and development, and innovations in the treatment landscape by various key Crohn's Disease companies such as Celgene, Eli Lilly and Company, Arena Pharmaceuticals, RedHill Biopharma, Janssen, AbbVie, Boehringer Ingelheim, and others.
DelveInsight's report titled "Crohn's Disease Market Insight, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/crohns-disease-cd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" offers a comprehensive analysis of the historical and projected market size for Crohn's disease from 2020 to 2034. The report examines various epidemiology segments and forecasts, explores market trends for Crohn's disease, assesses the competitive landscape, evaluates current and emerging therapeutic approaches, and identifies unmet needs in the treatment of Crohn's disease.
The report notes that the Crohn's Disease market across 7MM is expected to grow substantially over the next ten years from approximately USD 9 billion in 2023. This growth will be driven by the introduction of novel therapies with improved clinical profiles and more convenient routes of administration, a rise in the market penetration of targeted and advanced therapies, advancements in research and development, the identification of new biomarkers for diagnosing Crohn's disease, and an increasing prevalence of the condition.
Download the report to understand which factors are driving the Crohn's disease therapeutic market @ Crohn's Disease Market Trends [https://www.delveinsight.com/sample-request/crohns-disease-cd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
According to the report, the United States accounted for 80% of the total 7MM market share in 2023. Other significant markets, EU4 and the UK, made up approximately 17%, while Japan had the smallest market share at just 3%.
The report provides a comprehensive epidemiological analysis and forecasts extending to 2034. This analysis is segmented by total diagnosed prevalent cases, age-specific cases, severity-specific cases, and treated cases of Crohn's Disease. In 2023, there were approximately 2 million Crohn's Disease diagnosed prevalent cases in the 7MM, and this number is expected to increase during the forecast period. Additionally, age-specific data indicated that the highest prevalence of Crohn's Disease occurred in the age group of 18 to 44 years.
Discover evolving trends in Crohn's disease patient pool forecasts @ Crohn's Disease Epidemiology Analysis [https://www.delveinsight.com/sample-request/crohns-disease-cd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The Delveinsight report also discusses current diagnosis and treatment strategies for Crohn's Disease. There is no single test that can definitively confirm a Crohn's disease diagnosis, as its symptoms often resemble those of other conditions, including bacterial infections. A complete assessment, which includes clinical history, physical examination, and various diagnostic tests, is necessary for an accurate diagnosis.
Crohn's disease treatment decisions are guided by factors such as age, comorbidities, symptomatology, inflammation status, the disease location and extent, and the overall risk of developing a more severe or complicated disease. Currently, there is no cure for Crohn's Disease, so it is managed with corticosteroids, immunosuppressive medications, and biologics.
Some of the drugs approved for the management of Crohn's Disease include NTYVIO (Takeda Pharmaceutical), STELARA (Janssen Pharmaceuticals), CIMZIA (UCB), TYSABRI (Biogen), REMICADE (Janssen Biotech), HUMIRA (AbbVie), ALOFISEL (Takeda Pharmaceuticals), Budesonide (AstraZeneca/Tillotts Pharma), SKYRIZI (AbbVie and Boehringer Ingelheim), and RINVOQ (AbbVie).
Recently, in January 2025, OMVOH (Eli Lilly and Company) was approved by the FDA for treating moderately to severely active Crohn's disease in adults.
According to DelveInsight's Crohn's Disease Market Report, Adalimumab captured the highest market share for Crohn's Disease in 2023, with USD 3 billion across the 7MM.
Unlock which emerging Crohn's disease drug is expected to capture the largest market share in 7MM by 2034. Visit the Crohn's Disease Market Insights [https://www.delveinsight.com/sample-request/crohns-disease-cd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Despite significant advancements in treatment, existing therapies are associated with various challenges, such as side effects due to long-term use, high costs, patient adherence issues, healthcare burdens, and additional costs linked to complications from comorbidities. These factors highlight the urgent need for improved therapies for Crohn's Disease.
DelveInsight's analysis indicates that the current developmental pipeline for Crohn's Disease treatments is robust, with several companies initiating clinical trials for new options. The pipeline includes drugs such as Mirikizumab (Eli Lilly and Company), RHB-104 (edHill Biopharma), ZEPOSIA (Celgene), VELSIPITY (Arena Pharmaceuticals), TREMFYA (Johnson and Johnson), RYONCIL (Mesoblast), MT-1303 (Mitsubishi Tanabe Pharma Corporation), PRA023 (Prometheus Biosciences/Merck), AVB-114 (Avobis Bio LLC), ABX464 (Abivax S.A), and RVT-3101/PF-06480605 (Pfizer), among others .
In February 2025, the FDA granted Fast Track designation to AVB-114 (Avobis Bio LLC) for the treatment of Crohn's perianal fistulas. These recent developments indicate positive momentum in the field.
Although Crohn's disease poses significant challenges, such as the rise of biosimilars, delays in accurate diagnosis, and complications in treating patients with difficult-to-manage fistulas, the introduction of new therapies is expected to drive market growth.
Table of Contents
1.
Key Insights
2.
Report Introduction
3.
Crohn's Disease Market Overview at a Glance
4.
Executive Summary of Crohn's Disease
5.
Key Events
6.
Disease Background and Overview
7.
Methodology
8.
Epidemiology and Patient Population
9.
Patient Journey
10.
Marketed Therapies
11.
Emerging Therapies
12.
Crohn's Disease: Seven Major Market Analysis
13.
KOL Views
14.
SWOT Analysis
15.
Unmet needs
16.
Market Access and Reimbursement
17.
Appendix
18.
DelveInsight Capabilities
19.
Disclaimer
Related Reports
Crohn's Disease Pipeline Insight [https://www.delveinsight.com/report-store/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Crohn's Disease Pipeline Insight provides comprehensive insights about the Crohn's Disease pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Crohn's Disease companies, including Anssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Roche, Eisai, and Bristol-Myers Squibb among others.
About DelveInsight
DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=crohns-disease-market-across-the-7mm-to-witness-upsurge-in-growth-from-usd-9-billion-in-2023-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Crohn's Disease Market Across the 7MM to Witness Upsurge in Growth from USD 9 Billion in 2023 | DelveInsight here
News-ID: 3933543 • Views: …
More Releases from ABNewswire
Peer to Peer Network ($PTOP) Rockets into the Future: A New AI Division and a Bo …
Peer to Peer Network, Inc. ($PTOP), a publicly traded technology company primarily known for its MOBICARD Trademark digital business card platform, announced signing a Letter of Intent (LOI) with INS Digital Intelligence LLC to form a joint venture called PTOP Intelligence Lab, focused on developing proprietary artificial intelligence (AI) solutions for B2B markets. This collaboration, spearheaded by AI product specialist Derek McCarthy, intends to accelerate PTOP's growth by integrating AI…
Idiopathic Pulmonary Fibrosis Pipeline 2025: Latest FDA Approvals, Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Idiopathic Pulmonary Fibrosis pipeline constitutes 80+ key companies continuously working towards developing 100+ Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Idiopathic Pulmonary Fibrosis Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Idiopathic Pulmonary Fibrosis Market.
The…
Global Sound Reinforcement Market Set to Grow at 4.28% CAGR, Reaching USD 38.58 …
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025-2030.
The global sound reinforcement market [https://www.arizton.com/market-reports/sound-reinforcement-market-size-growth] is projected to expand from USD 30 billion in 2024 to USD 38.58 billion by 2030, growing at a steady 4.28% CAGR, according to Arizton. This growth is being driven by rising demand for high-quality audio solutions across live events and entertainment venues. Advances in audio technology have significantly enhanced…
Gelt Raises $13M Series A to Expand AI-Powered Tax Solutions for Real Estate Inv …
Miami, FL - September 30, 2025 - Gelt [https://www.joingelt.com/], the first AI-native tax firm for investors and the Top 1% in the U.S., today announced it has raised $13 million in Series A [https://www.businesswire.com/news/home/20250930325477/en/Gelt-the-First-AI-Native-Tax-Firm-Raises-%2413M-in-Series-A-Funding-to-Transform-Tax-Strategy-Into-Year-Round-Wealth-Optimization], bringing its total funding to $21.2 million. Global investors, Zvi Limon of the Rimon Group, Vintage Investment Partners, and TLV Partners led the funding. As part of the launch, Yoram Tietz, former Managing Partner at EY…
More Releases for Crohn
Global IBD Ulcerative Colitis And Crohn S Disease Treatment Industry Poised for …
The IBD Ulcerative Colitis And Crohn S Disease Treatment Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2024 and 2032. Similar to a compass, it helps businesses navigate the market's complexities by showcasing both the present situation and the newest developments influencing its direction. For businesses, stakeholders, and industry participants, this report serves as…
Global Companion Animal Specialty Drugs and Crohn s Disease Drug (COVID-19 Imapa …
The Companion Animal Specialty Drugs Market ( https://bit.ly/31KDIZZ ) report is intended to function as a supportive means to assess the Companion Animal Specialty Drugs market along with the complete analysis and clear-cut statistics related to this market. In other words, the report would provide an up-to-date study of the market in terms of its latest trends, present scenario, and the overall market situation. Further, it will also help the…
Crohn’s Disease Drugs Market Research and Clinical Analysis 2020 - Bayer AG, Amg …
The Crohn's Disease Drugs Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Order a Copy of…
Crohn s Disease Drug Market to Witness Huge Growth by 2025 | AbbVie, Janssen Bio …
HTF MI recently introduced Global Crohn s Disease Drug Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are AbbVie, Janssen Biotech, UCB, Amgen, Tillotts Pharma & Takeda…
Crohn Disease Market 2018 by its Scientific Reviews, Clinical Application and Ke …
Global Crohn Disease Market Professional Survey Report 2018 to 2025 presents an in-depth assessment of the Crohn Disease Market including enabling key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Crohn Disease Market investments from 2018 till 2025.
This study answers several questions for stakeholders, primarily which market segments…
Crohn Disease Market Set for Expansive Growth by 2022
This report studies the global Crohn Disease market, analyzes and researches the Crohn Disease development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
Johnson & Johnson
Pfizer
Sanofi
Merck
GSK
AbbVie
Takeda
Ferring
UCB
Boehringer Ingelheim
Ask for sample copy @ http://www.researchtrades.com/request-sample/1117798
Market segment by Regions/Countries, this report covers
United States
EU
Japan
China
India
Southeast Asia
Market segment by Type, Crohn Disease can be split into
Small Intestine and Ileocephalitis
Colon Disease
Market segment…
